RotaTeq® Proves to Maintain High Clinical Efficacy Two Years Post-Vaccination in Europe

In a new analysis data in the European subgroup of the large clinical study REST (Rotavirus Efficacy and Safety Trial), the five-type rotavirus vaccine RotaTeq® demonstrated 100% clinical efficacy against severe rotavirus disease for the first rotavirus season after vaccination. The efficacy remained high through two rotavirus seasons of follow up, preventing 98% of severe rotavirus cases. This new sub-analysis was presented last week at the 25th International Congress of Paediatrics in Athens.

Results across four Phase II/Phase III clinical trials in different regions of the world, including the complete REST study with nearly 70,000 infants enrolled worldwide, already supported the consistently high clinical efficacy of 98% to 100% of RotaTeq® in the prevention of severe rotavirus disease due to virus types directly targeted by RotaTeq®.

In this REST sub-analysis, assessing the response of more than 30 000 European infants, RotaTeq® has also proved to reduce the number of hospitalisations and emergency room visits by 95%d and to lower the number of office visits by 87%, up to two years post vaccination in Europe, due to serotypes G1 to G4.

"These data all together demonstrate that there is highly consistent and lasting protection across multiple studies of RotaTeq® and illustrates the public health benefit of this vaccine" said Timo Vesikari, Professor of Virology and Head of the Division of Paediatric Infectious Diseases at the University of Tampere, Finland. "Moreover, as rotavirus peak is between 6 and 24 months of age, it is important to vaccinate infants before 6 months of age and to ensure sufficiently long protection".

RotaTeq® is the only five-type rotavirus vaccine offering direct and broad protection against the five rotavirus types that cause more than 98% of paediatric rotavirus diseases in Europe (G1, G2, G3, G4 and G9). In the European Union (25 member states), RotaTeq® has been approved in June 2006; it is already available in 11 countries and being launched in several others.

Rotavirus is the most common cause of severe dehydrating diarrhoea in children worldwide and virtually all children will be infected with rotavirus within the first five years of life. Rotavirus disease is a leading cause of infant hospitalisation due to gastroenteritis in Europe.

About Sanofi Pasteur MSD
Sanofi Pasteur MSD is a joint venture between sanofi pasteur, the vaccine division of sanofi-aventis, and Merck & Co., Inc. Combining innovation and expertise, Sanofi Pasteur MSD is the only company in Europe dedicated exclusively to vaccines. Sanofi Pasteur MSD is able to draw on the research expertise of sanofi pasteur and Merck & Co., Inc., together with their teams throughout the world, to focus on the development of new vaccines for Europe, which aim to extend protection to other diseases and perfect existing vaccines in order to improve the acceptability, efficacy and tolerability of vaccination. For furhter information, please visit www.spmsd.com

Most Popular Now

Pfizer's elranatamab granted FDA Breakthrough Ther…

Pfizer Inc. (NYSE:PFE) announced its investigational cancer immunotherapy, elranatamab, received Breakthrough Therapy Designation from the U.S. Food and Drug Administrati...

Salvat Laboratories announces submission of New Dr…

Salvat Laboratories announced that it has submitted a New Drug Application (NDA) to the FDA for the approval of the first ocular corticosteroid formulated in a nanoemulsi...

New insights on antibody responses to Omicron vari…

Knowing how well vaccination against one SARS-CoV-2 strain (with or without previous infection) counteracts infection with a different strain is a critical research quest...

The origin-of-life molecule, a key to cancer resea…

RNA, the molecule that gave rise to life, has been shown to be essential for repairing human genetic material and preventing mutations that might lead to developing cance...

Bayer with continued strong performance

The Bayer Group maintained its strong business performance across all three divisions in the third quarter. "Despite rising inflation and global supply chain problems, we...

Vividion Therapeutics names Jenna Goldberg as Chie…

Vividion Therapeutics, Inc., a biopharmaceutical company utilizing novel discovery technologies to unlock high value, traditionally undruggable targets with precision the...

Sugar molecules as a target in cancer therapy

Cancer cells use sugar molecules on their surface to disable attacks by the body's immune system. Researchers at the University of Basel now report on how this mechanism ...

COVID vaccination improves effectiveness of cancer…

Patients with nasopharyngeal cancer are often treated with drugs that activate their immune system against the tumor. Until now, it was feared that vaccination against Co...

Pfizer and BioNTech receive positive CHMP opinion …

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY® Original/Omicron ...

Making melanoma immortal: Pitt scientists discover…

Scientists at the University of Pittsburgh School of Medicine have discovered the missing puzzle piece in the mystery of how melanoma tumors control their mortality. I...

Study reveals vaccine confidence declined consider…

A new study suggests that, despite the success of the COVID-19 vaccination campaigns, vaccine confidence has declined significantly since the start of the pandemic. Re...

New drug shows promise for fighting both COVID-19 …

While vaccination can provide life-saving protection against COVID-19, scientists are still searching for ways to treat severe infections, including in people who cannot ...